Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany

Nikolaus Feucht, Huebner Matthias, Chris P Lohmann, Mathias MaierAugenklinik rechts der Isar, Technical University Munich, GermanyBackground: The VEGF Inhibition Study In Ocular Neovascularisation (VISION) reported the efficacy of intravitreal (ITV) vascular endothelial growth factor (VEGF) inhibiti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nikolaus Feucht, Huebner Matthias, Chris P Lohmann, Mathias Maier
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/1838ae1e36ea4499a245288089b7533d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1838ae1e36ea4499a245288089b7533d
record_format	dspace
spelling	oai:doaj.org-article:1838ae1e36ea4499a245288089b7533d2021-12-02T07:05:01ZPegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany1177-54671177-5483https://doaj.org/article/1838ae1e36ea4499a245288089b7533d2008-06-01T00:00:00Zhttp://www.dovepress.com/pegaptanib-sodium-treatment-in-neovascular-age-related-macular-degener-a1777https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Nikolaus Feucht, Huebner Matthias, Chris P Lohmann, Mathias MaierAugenklinik rechts der Isar, Technical University Munich, GermanyBackground: The VEGF Inhibition Study In Ocular Neovascularisation (VISION) reported the efficacy of intravitreal (ITV) vascular endothelial growth factor (VEGF) inhibition with pegaptanib sodium (Macugen&reg;) for the treatment of neovascular age-related macular degeneration (AMD). This paper reports clinical experience with pegaptanib sodium for the treatment of occult or minimally classic choroidal neovascularization (CNV) due to AMD.Material and methods: The study included 50 eyes (in 49 patients) with either occult CNV or minimally classic CNV secondary to neovascular AMD who were not eligible for photodynamic therapy (PDT). Study data were analyzed retrospectively. During the 6-month study, patients were administered an average 2.74 injections of 0.3 mg ITV pegaptanib sodium. Angiography and optical coherence tomography (OCT) examinations were carried out and intraocular pressure (IOP) and visual acuity (VA) were measured at baseline, at 3 months and at 6 months. An eye examination was performed and VA was measured the 2 days following treatment and then again at weeks 4&ndash;6, and at 3 and 6 months. OCT, VA, and IOP were also assessed at 1 month.Results: ITV pegaptanib sodium was well tolerated and no treatment complications arose. Mean VA was measured as: 0.37 &plusmn; 0.24 at baseline; 0.37 &plusmn; 0.25 at 1 month; 0.37 &plusmn; 0.25 at 3 months and 0.40 &plusmn; 0.26 at 6 months. VA was stabilized in approximately 90% of eyes treated with pegaptanib sodium. OCT examination showed a minimal change in central retinal thickness (CRT) during the course of the study, from 251.19 &micro;m at baseline to 251.63 &micro;m at 6 months. No elevation in IOP was measured during treatment at 4&ndash;6 months in patients receiving pegaptanib sodium.Conclusions: ITV therapy with pegaptanib sodium for occult and minimally classic CNV secondary to neovascular AMD offered good efficacy with a favorable adverse events profile. The majority of patients showed stabilization in all assessed parameters. In clinical practice, careful consideration should be given to the use of nonselective VEGF inhibition in patients with a high cardiovascular risk profile or in those with a history of thromboembolic events.Keywords: Intravitreal (ITV) injection, age-related macular degeneration (AMD), choroidal neovascularization (CNV), anti-VEGF therapy, pegaptanib sodium Nikolaus FeuchtHuebner MatthiasChris P LohmannMathias MaierDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2008, Iss Issue 2, Pp 253-259 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Nikolaus Feucht Huebner Matthias Chris P Lohmann Mathias Maier Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany
description	Nikolaus Feucht, Huebner Matthias, Chris P Lohmann, Mathias MaierAugenklinik rechts der Isar, Technical University Munich, GermanyBackground: The VEGF Inhibition Study In Ocular Neovascularisation (VISION) reported the efficacy of intravitreal (ITV) vascular endothelial growth factor (VEGF) inhibition with pegaptanib sodium (Macugen&reg;) for the treatment of neovascular age-related macular degeneration (AMD). This paper reports clinical experience with pegaptanib sodium for the treatment of occult or minimally classic choroidal neovascularization (CNV) due to AMD.Material and methods: The study included 50 eyes (in 49 patients) with either occult CNV or minimally classic CNV secondary to neovascular AMD who were not eligible for photodynamic therapy (PDT). Study data were analyzed retrospectively. During the 6-month study, patients were administered an average 2.74 injections of 0.3 mg ITV pegaptanib sodium. Angiography and optical coherence tomography (OCT) examinations were carried out and intraocular pressure (IOP) and visual acuity (VA) were measured at baseline, at 3 months and at 6 months. An eye examination was performed and VA was measured the 2 days following treatment and then again at weeks 4&ndash;6, and at 3 and 6 months. OCT, VA, and IOP were also assessed at 1 month.Results: ITV pegaptanib sodium was well tolerated and no treatment complications arose. Mean VA was measured as: 0.37 &plusmn; 0.24 at baseline; 0.37 &plusmn; 0.25 at 1 month; 0.37 &plusmn; 0.25 at 3 months and 0.40 &plusmn; 0.26 at 6 months. VA was stabilized in approximately 90% of eyes treated with pegaptanib sodium. OCT examination showed a minimal change in central retinal thickness (CRT) during the course of the study, from 251.19 &micro;m at baseline to 251.63 &micro;m at 6 months. No elevation in IOP was measured during treatment at 4&ndash;6 months in patients receiving pegaptanib sodium.Conclusions: ITV therapy with pegaptanib sodium for occult and minimally classic CNV secondary to neovascular AMD offered good efficacy with a favorable adverse events profile. The majority of patients showed stabilization in all assessed parameters. In clinical practice, careful consideration should be given to the use of nonselective VEGF inhibition in patients with a high cardiovascular risk profile or in those with a history of thromboembolic events.Keywords: Intravitreal (ITV) injection, age-related macular degeneration (AMD), choroidal neovascularization (CNV), anti-VEGF therapy, pegaptanib sodium
format	article
author	Nikolaus Feucht Huebner Matthias Chris P Lohmann Mathias Maier
author_facet	Nikolaus Feucht Huebner Matthias Chris P Lohmann Mathias Maier
author_sort	Nikolaus Feucht
title	Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany
title_short	Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany
title_full	Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany
title_fullStr	Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany
title_full_unstemmed	Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany
title_sort	pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in germany
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/1838ae1e36ea4499a245288089b7533d
work_keys_str_mv	AT nikolausfeucht pegaptanibsodiumtreatmentinneovascularagerelatedmaculardegenerationclinicalexperienceingermany AT huebnermatthias pegaptanibsodiumtreatmentinneovascularagerelatedmaculardegenerationclinicalexperienceingermany AT chrisplohmann pegaptanibsodiumtreatmentinneovascularagerelatedmaculardegenerationclinicalexperienceingermany AT mathiasmaier pegaptanibsodiumtreatmentinneovascularagerelatedmaculardegenerationclinicalexperienceingermany
_version_	1718399618540109824

Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany

Ejemplares similares